One of Britain’s leading life sciences companies is to be taken over by an American group in a $5.7 billion deal after its founder called for a change in strategy.
Cambridge-based Abcam is a global supplier to the pharmaceuticals research industry. Quoted on Nasdaq, the technology-heavy New York stock exchange, it has agreed to a $24-per-share offer from Danaher under which it would continue as a standalone entity within the parent group.
The offer represents a 2.7 per cent premium to its closing price last week. Abcam shares fell by 4.3 per cent, or $1.01, to $22.35 on Wall Street last night.
Abcam was founded in 1998 and is a key supplier of antibodies and other materials used by about 750,000 researchers in the life
© Times Media Limited 2023.